Background Type 2 biomarkers that predict both likelihood of future severe exacerbations
and response to mAb therapy in asthma would be useful clinically in identifying patients both …

We investigated the time course of change of type-2 asthma biomarkers after a severe
asthma exacerbation. Blood eosinophils were lowest immediately after treatment was …

To the Editor: Periostin is a matricellular protein upregulated by IL-4 and IL-13 and released
by airway epithelial cells. Its levels in peripheral blood are associated with eosinophilic …

Background Periostin has been shown to be a marker of Type 2 airway inflammation,
associated with airway eosinophilia. It has a potential role in identifying asthmatics who may …

Background In asthma, serum periostin may potentially be used as a biomarker in the
management of patients with Type-2 eosinophilic airway inflammation. However, serum …

Background Asthma is the most common chronic childhood respiratory condition globally.
Inhaled corticosteroid (ICS)–formoterol reliever-based regimens reduce the risk of asthma …

Objectives To estimate the proportion of adult diabetics with a skin to deltoid muscle
distance (SDMD) of> 25 mm, representing a distance greater than the standard needle …

Background High-concentration oxygen therapy causes increased arterial partial pressure
of carbon dioxide (PaCO 2) in patients with COPD, asthma, pneumonia, obesity and acute …

Asthma is a common, heterogeneous condition where current treatment options are limited
to a 'one size fits all'approach. Biological therapies targeting specific components of the …

Introduction: Many candidate treatable traits have been proposed for the management of
airways disease. However, trait prevalence in the general asthma population and which …